Last quarter (Q0 0), TNF Pharmaceuticals's total revenue was $―, a decrease of ― from the same quarter last year. In Q0, TNF Pharmaceuticals's net income was $-2.68M. See TNF Pharmaceuticals’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 23	Dec 22	Dec 21	Dec 20
Total Revenue	$ ―	$ ―	$ ―	$ ―	$ ―
Cost of Revenue	$ ―	$ ―	$ ―	$ -15.04M	$ -2.01M
Gross Profit	$ ―	$ ―	$ ―	$ 15.04M	$ 2.01M
Operating Expense	$ 4.74M	$ 16.36M	$ 15.28M	$ 12.56M	$ 5.10M
Operating Income	$ -11.82M	$ -15.60M	$ -15.28M	$ -28.81M	$ -9.49M
Net Non Operating Interest Income Expense	$ ―	$ -455.57K	$ ―	$ ―	$ ―
Other Income Expense	$ -5.96M	$ 11.90M	$ -76.54K	$ -1.09M	$ -141.00
Pretax Income	$ -17.25M	$ -4.00M	$ -15.20M	$ -29.89M	$ -9.49M
Tax Provision	$ ―	$ 4.13M	$ -5.91M	$ -6.22M	$ -1.96M
Earnings From Equity Interest Net Of Tax	$ ―	$ ―	$ ―	$ ―	$ ―
Net Income Common Stockholders	$ -21.14M	$ -8.22M	$ -15.21M	$ -29.89M	$ -9.49M
Basic EPS	$ -8.98	$ -5.33	$ -0.39	$ -25.50	$ -298.80
Diluted EPS	$ -8.98	$ -5.33	$ -0.39	$ -25.50	$ -298.80
Basic Average Shares	$ 8.33M	$ 1.54M	$ 38.83M	$ 1.17M	$ 117.54K
Diluted Average Shares	$ 8.33M	$ 1.54M	$ 38.83M	$ 1.17M	$ 117.54K
Dividend Per Share	$ ―	$ ―	$ ―	$ ―	$ ―
Total Operating Income As Reported	$ ―	$ ―	$ ―	$ ―	$ ―
Reported Normalized Basic E P S	$ ―	$ ―	$ ―	$ ―	$ ―
Reported Normalized Diluted E P S	$ ―	$ ―	$ ―	$ ―	$ ―
Rent Expense Supplemental	$ ―	$ ―	$ ―	$ ―	$ ―
Total Expenses	$ 4.74M	$ 16.36M	$ 15.28M	$ -2.48M	$ 3.09M
Net Income From Continuing And Discontinued Operation	$ -18.41M	$ -4.00M	$ -15.20M	$ -29.89M	$ -9.49M
Normalized Income	$ -8.19M	$ ―	$ ―	$ ―	$ ―
Interest Expense	$ ―	$ ―	$ ―	$ ―	$ ―
EBIT	$ -12.57M	$ 129.05K	$ -15.20M	$ -29.28M	$ -8.30M
EBITDA	$ -12.57M	$ 129.05K	$ -15.20M	$ -29.28M	$ -8.28M

Currency in USD

TNF Pharmaceuticals Earnings and Revenue History

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing